The inhibitory effect and targets of CRM197 on tumor growth in arsenic-transformed cells and lung cancer cells.

ABSTRACT: Lung squamous cell carcinoma (LSCC) is among the most prevalent and deadly malignancies in arsenic-exposed populations, yet effective targeted therapies remain elusive. Cross-Reactive Material (CRM197), a non-toxic mutant of diphtheria toxin that binds heparin-binding EGF‑like growth factor (HB‑EGF), has demonstrated anti‑tumor activity, but its efficacy against arsenic-induced LSCC has not been characterized. In this study, we assessed CRM197's effects on proliferation (CCK‑8 and colony‑formation assays), cell‑cycle progression (flow cytometry), comparing its activity to cetuximab and afatinib in arsenic‑transformed BEAS‑2B cells obtained by 6-month treatment on human bronchial epithelial cells BEAS-2B with low-dose sodium arsenite (As‑T) and lung cancer cells(NCI‑H226 and PC‑9). Next, we

SUBMITTER: Zhang X 

PROVIDER: S-EPMC12623889 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature